Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05058729 · ClinicalTrials.gov registry record
MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 1,507
- Enrollment target
NCT05058729: Completed study, sponsored by Biogen.
NCT05058729 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 1,507 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05058729 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 1,507 participants
- Enrollment target
Study Summary
The primary objective of this sub-study is to supplement the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) dataset with coronavirus disease 2019 (COVID-19)-related health information obtained from periodic participant questionnaires administered by participating MS PATHS institutions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,507 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2021-10-08 |
What the finished NCT05058729 record still lists
NCT05058729 is an observational study that tracks outcomes without assigning an intervention. Its 1,507 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05058729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05058729 about?
NCT05058729 is a clinical study titled "MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study". The primary objective of this sub-study is to supplement the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) dataset with coronavirus disease 2019 (COVID-19)-related health information obtained from periodic participant questionnaires administered by participating MS...
What is the current status of trial NCT05058729?
This trial is currently completed. The enrollment target is 1,507 participants. The study started on 2020-12-07. Estimated completion is 2021-10-08.
Who is sponsoring clinical trial NCT05058729?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI